Abstract
A c c e p t e d M a n u s c r i p t that may account for the apparent enrichment observed in culture experiments [5] . Indeed, if cART is interrupted, the HIV production by these cells is observed within 2 to 4 weeks. Thus, in the absence of cART, cells that harbour quiescent replication-competent virus can rekindle HIV replication and transmission [1] . Recently an alternative and broader definition of viral reservoir has been suggested: all infected cells containing all forms of HIV persistence that can participate in HIV pathogenesis [6] . This broader definition includes defective proviruses that could theoretically play a role in HIV pathogenesis through the production of viral proteins and the subsequent induction of chronic immune activation [7] . In other words, proviruses that are not fully replication-competent, but that are capable of transcribing viral mRNAs and/or translating viral proteins, may constitute an additional dimension to persistence studies [8] .
Moreover, a chronic state of immune activation combined with a persistent pro-inflammatory state leads to a premature aging and to an increased frequency of non-AIDS related illness [9] . In the context of a possible virological control with a deferred progression of HIV infection due to cART, the focus in HIV research is now posed on the possibility of HIV control in the absence of cART and, in the end, on the possibility of HIV complete eradication from the body. The greatest challenge in the prospect to achieve a cure of HIV infection is to eliminate all replication-competent virus in the reservoir or, if this could not be achieved, to obtain a lifelong remission without the use of cART. Several strategies have been addressed both in animals and human models but nowadays all have failed to achieve HIV cure [10] . In fact, the only patient who have been cured from HIV infection was the so-called "Berlin patient". Timothy Brown received a hematopoietic stem cell transplant from a donor whose cells were resistant to HIV infection due A c c e p t e d M a n u s c r i p t 5 to the delta32 mutation in the HIV coreceptor CC chemokine receptor 5 (CCR5). Mr. Brown, who has not been receiving cART for more than 10 years, has no evidence of replication-competent HIV [11] . Although the transplantation approach is intriguing, it has to be considered just a proof of concept for possible future eradication strategies due to the high mortality risk for the patient and also to the large cost.
In this review we are going to examine all the possible pharmacological approaches that have been tested, the one which still are ongoing in trial and also the future perspectives regarding HIV cure.
Very early treatment and ART free remission
Several studies have assessed the possibility of reducing the viral reservoir and consequently to pose the foundation for a possible HIV cure by using cART in the early phase of infection. These studies start from the observation that HIV reservoir begins to increase dramatically as soon as HIV-RNA becomes detectable in plasma and it persists to increase in the following weeks [12] . One of the strategies tested was treatment intensification during the early stage of HIV infection: the addition of maraviroc to a cART regimen results in faster reduction of 2-long terminal repeat (LTR) newly infected cells and recovery of CD4 T-cell counts, and a modest reduction in total reservoir size after 48 weeks of treatment. However, CCR5 blockade also induced a slower decrease in plasma viremia and immune activation [13] . As shown by Crowell and colleagues, the presence of detectable colonic HIV RNA at the time of cART initiation during acute HIV infection, resulted associated with higher levels of proviral DNA suggesting that the seeding of HIV in the gut may have long-lasting effects on the size of persistent viral reservoirs and may represent an important therapeutic target in eradication strategies [14] . Due to its rapid infiltration by HIV during the early phase of infection, the colon may be a target to reduce the rapid instauration of the reservoir. A possible intervention designed to prevent colonic infiltration could be the use of anti-α4β7 monoclonal antibody administration, to block the interaction between the HIV envelope and gut-homing integrins. This kind of intervention has to be conducted before peripheral blood HIV RNA reaches peak levels. In animal model, anti-α4β7 has been able to prevent mucosal infection by simian immunodeficiency virus and in the early phase of infection it is able to protect both blood and gut-associated lymphoid tissue CD4 T cells from A c c e p t e d M a n u s c r i p t 6 infection [15] . Another potential intervention tested during SIV acute infection in rhesus macaques is the caspase inhibitor Q-VD-OPH which demonstrated first of all to reduce T cell death, secondly to preserve of CD4 + /CD8 + T cell ratio in lymphoid organs and in the gut and also to maintain memory CD4 + T cells with increased specific CD4 + T cell response with the production of cytotoxic molecules [16] . If it is true that very early cART start, within 2 weeks from HIV infection, could significantly reduce the size of viral reservoir, making almost impossible its quantification, unfortunately, it does not correspond to a significant clinical improvement for the patient [17] . In fact, infection rebounds when treatment is interrupted by reactivation of virus production from this reservoir [18] . This finding was also confirmed in subjects treated in an extremely early phase of HIV infection, i.e. Fieibig I stage, leading to an almost complete undetectability of HIV-DNA in blood and tissue sampled. However, it is possible that the very small size of the latently infected cells could lead to a delayed rebound of HIV viremia [19, 20] . Lymphoid tissues are the principal sites of production and persistence before initiating cART and if cART is interrupted a rebound of the plasmatic HIV-RNA is observed shortly thereafter. One possible explanation about the persistent replication of HIV at tissue level, albeit an undetectable HIV-RNA in plasma, could be a low penetration of antiretrovirals in lymphoid tissues despite therapeutic concentrations obtained in blood [21] . Sequence analysis revealed a great number of rebounding viruses representing recrudescent viremia from multiple sources. These findings suggest that the HIV reactivation arises from many latently infected cells at multiple sites. Unfortunately, the large pool of cells and sites that are able to rekindle recrudescent infection highlights the challenges in eradicating HIV [22] . The first data showing a possible role in HIV "functional" cure of early antiretroviral treatment came from the VISCONTI study in which 14 patients, who initiated cART within 3 months of their estimated date of infection, remained on durable treatment for 1-8 years controlling HIV replication after cART interruption [23, 24] . The so-called "post-treatment controllers" have maintained their plasma HIV RNA levels to <50 copies per mL, with the exception of a few viral blips with a good median CD4 cell count after cART interruption. Apart from the VISCONTI cohort, amid patients there have also been other anecdotal reports of post treatment controllers [25] . The patient's subsets with primary HIV infection are the ideal candidates for intervention strategies with therapeutic vaccines. Such A c c e p t e d M a n u s c r i p t 7 interventions could lead to an interruption of cART with a control of HIV replication hopefully through the employment of a "functional cure" ,since unfortunately they cannot cause an HIV eradication [26] . The eradication strategy of a very early cART treatment has not worked even in children, who are in many ways the best population to apply it [27, 28] . To achieve sustained virological control of HIV-1, without the need of continuous cART, and to clear virus-expressing cells, it is likely that immune-based therapies will be needed, nevertheless therapeutic HIV vaccine trials in chronic HIV infection have obtained very few clinical benefits. The subset of subjects with a primary HIV infection is a specific target population allowing to study the role of HIV therapeutic vaccines in individuals who have experienced an early cART start. It was observed that this approach has led to few or no viral escape, less CD4 depletion and more preserved memory T cells.
In conclusion if on the one hand it is unlikely that future improvement in cART strategies could led to a potential HIV "functional" cure on the other hand more studies are required for the characterization of immune responses following treatment initiation at different stages of primary HIV infection, since responses to therapeutic vaccines may vary depending on the pre-existing HIV-specific immune responses [26] .
Shock and Kill strategies
The most explored strategy in tackling HIV-1 reservoirs -"shock and kill" -describes the broadly explored pharmacological way of kicking the latent provirus, with subsequent killing of the virus-producing cells by the immune system [29] . One strategy to eliminate latency is to activate virus production using latency reversing agents (LRAs) with the goal of triggering cell death through virus-induced cytolysis or immunemediated clearance. However, multiple studies have demonstrated that activation of viral transcription alone is insufficient to induce cell death and some LRAs may counteract cell death by promoting cell survival. Some have advocated approaches that activate latent reservoir cells, thereby allowing them to be destroyed. Clinical trials of such latency-reversing classes of drugs like histone deacetylase inhibitors (HDACi) suggest that they can induce some expression of latent HIV although not its clearance [30] . Other A c c e p t e d M a n u s c r i p t 8 drug classes, such as activators of protein kinase C or toll-like receptors, may be more effective [31] . Given potentially large HIV reservoirs , the extent to which these agents could provide adequate awakening of latent virus is unclear [32] . Their potential role should not just be considered alone but combined together with an immune-based therapy to kill the re-activated cells. [33] . First of all, it is worth mentioning the valproic acid, a well-known drug used commonly against seizures or migraine, which emerged as a potential LRA thank to a study supervised by Margolis and published on Lancet in 2005. This work gained such huge resonance because scientists noticed that three out of four patients, under a HAART regimen and successfully suppressed, underwent a significant decrease in the frequency of latently infected CD4+ T-cells when enfuvirtide and valproic acid were added for 12 weeks [34] . Although this work presented many weak points such as the fact that it was not controlled, the impossibility to quantify the effect of the single drug, or again that the number of CD4+ T cell is significantly fluctuant even in stable patients , it raised great enthusiasm about the subject [35] . However successive research failed to confirm such promising results, defining the usefulness of valproic acid addition of limited value [36] [37] [38] . Next, vorinostat administration has led to an increase in cell-associated HIV RNA within circulating resting cd4+ t cells in patients under cART [30, 39] . However, there is not an agreement about the dose regimen to apply in order to obtain a complete depletion of the reservoirs [40, 41] . Another potent member of these series is panobinostat, A c c e p t e d M a n u s c r i p t 9 which demonstrated to be able to reverse latency with a high level both of cell-associated unspliced HIV RNA and plasma viremia other than to increase the amount of sytemic histone acetilation both in vitro and in BLT (bone marrow, liver, thymus) mice [42, 43] . Despite these promising results, panobinostat has not proved to obtain a drop in the levels of latent-infected CD4+ T cells suggesting that a combination therapy may be necessary [42, 43] . Finally, romidespin has to be mentioned within the HADC pool of compounds. It has shown to be able to induce HIV expression ex vivo at concentrations that can be achieved clinically,
indicating that the drug may reactivate latent HIV in patients on suppressive cART and also resulted much more potent than its above-mentioned counterparts [44] . Romidepsin has also displayed significant viral evidence may suggest that a specific subset of transcriptionally activated proviruses contributed to the majority of viremia [46] .
Several bromodomain inhibitors have been investigated in vitro as possible compounds able to reactivate
HIV-1 latent proviruses [47] . Bromodomain and extraterminal (BET) protein family is a highly-conserved class of transcriptional regulators that are characterized by the presence of tandem bromodomains, conserved domains that recognize and bind acetyl-lysine residues, and a so-called extraterminal (ET)
domains. BRD4 represents the best-studied BET family member, which contains a domain, namely the A c c e p t e d M a n u s c r i p t 10 positive transcription elongation factor b (P-TEFb)-interacting domain, that binds the HIV cofactor P-TEFb [48] . Such bond prevents the reaction between HIV Tat and P-TEFb, which is crucial to trigger HIV transcription. Thus, BRD4 represents a potent HIV activation inhibitor [49] . In the light of these experimental observations, the bromodomain inhibitor JQ1, a cell-permeable compound with potent anticancer activity, which prevents the sequestration of P-TEFb by BRD4 hence promoting Tat-transactivation, has been recruited amid the strategies to disrupt HIV latency [48] [49] [50] . Li et al. demonstrated in vitro that the binding of JQ1 with BRD4 enhances HIV transcription [49] . It seems, indeed, that JQ1 is able to dissociate BRD4 from the HIV promoter thus allowing the Tat transcriptional activity [49] . Although Li et al claimed that JQ1 activity is TAT-dependent, a study by Boehm et al. showed that even after the removal of
Tat from the equation, cells treated with JQ1 were able to start transcription [48] . They also demonstrated a role, even if of minor relevance than BRD4, of BRD2 in the activation of HIV transcription: knockdown of BRD2 resulted in a robust activation of the HIV LTR, and this effect was only slightly enhanced in response to JQ1 [49] .
Among LRA, disulfiram has been initially tested in HIV infected patients on stable cART to study the ability to induce plasma viremia since in vitro studies have demonstrated the capacity of this compound of inducing HIV transcription in a T cell model [51] . Despite the mechanism of action is not completely understood, It appears to be mediated by the depletion of the phosphatase and tensin homolog and the activation of protein kinase B [52] . Even though a rapid increase in the HIV viremia soon after the disulfiram administration, which resulted well tolerated, no effect on the size of HIV reservoir was observed in a pilot study by Spivak et al [53] . In a phase 2 study escalating doses of disulfiram were tested showing an increase in the cell-associated unspliced HIV-RNA at all doses [54] . The illustrated findings, combined with the good tolerability profile of this drug, suggest the possibility of use of disulfiram as LRA alone or combined with other molecules [55] .
Other key molecular mechanisms involved in HIV-1 latency are sequestration of transcription initiation/elongation factors and blockade of the assembly of the active elongation factor, P-TEFb. The NF-A c c e p t e d M a n u s c r i p t
11 κB pathway appears to be one of the most relevant pathways concerning HIV-1 reactivation. Protein kinase C agonists (PKCA) activate PKC isoforms which then phosphorylate IκB and consequently activate NF-κB.
Several PKC agonists have been considered for purging the reservoirs of latent HIV-1 [56] . First of all, prostratin is a unique phorbol esterthat it induces potent T cell activation signals and is not tumorigenic.
Besides the ability of prostratin to induce T-cell activation through PKC, without tumor promoting ability, another unique property is that, despite being able to reactivate latent HIV-1, it exerts an inhibitory effect on active HIV-1 replication through downregulation of CD4 [57] . Furthermore, bryostatin-1 has appeared to be an effective reversing agent. Bryostatins represent an important group of pharmaceutically promising substances. These compounds are produced by commensal microorganisms naturally occurring in marine invertebrates, mainly in bryozoans. The most frequently investigated substance is bryostatin-1, which is a highly oxygenated macrolide with a polyacetate backbone [58] . Its mechanism of action involves a bound to the diacylglycerol-binding region within the C-1 regulatory domain of PKC. Bryostatin-1 has shown to reactivate latent HIV-1 in vitro in monocytoid and lymphoid cell line models of latency and was approximately 1,000-fold more potent than prostratin [57] . However, since economic and environmental factors have severely limited its availability, De Cristopher et al. reported the activity of seven bryostatin-1 analogues, dubbed "bryologs", specifically designed to obtain molecules easier to operate with. These compounds incorporate a tetrahydropyranyl B-ring formed through a versatile prins macrocyclization. They demonstrated that these simplified bryostatin analogues, which share the functional activity of the clinical candidate prostratin, are up to four orders of magnitude more potent [59] .
Although research on latency reversing agents has collected a good amount of promising results, none of these compounds has provided an effective reduction in HIV reservoir size. Thus, scientists have been proposing combinations of different agents in order to obtain a maximal synergistic effect able to cause a significant contraction to the viral latent pool. First of all, it is worth mentioning the work of Reuse et al.
who tested the combined effect of prostatin (PKC agonists) and several HADCis [60] . They demonstrated that the combination of prostratin plus valproic acid or suberoylanilide hydroxamic acid disrupted more load [60] . Interestingly, they also found that HADCis can degrade cytoplasmic IκBα which enhances the PKC agonistic activity hence boosting their combined synergism [60] . Moreover, they proved that this combination is effective on all the viral subtypes belonging to the HIV group M except for subtype G [60] .
Secondly, Darcis et al. later considered the combination of PKC agonists and P-TEFb releasing compounds like JQ1 and the results obtained were quite promising. Initially they assessed the capability of these drugs of reaching a synergistic effect if administered together, so they measured the HIV-1 production and transcription both in U1 and in a J-Lat strain. They discovered that the combination PKC agonists plus iBET/hexamethylene bisacetamide strongly enhanced both production and transcription in such in vitro post-integration latency cellular models of T-lymphoid and myeloid lineages [61] . Furthermore, the combined effect of these molecules was tested ex vivo on primary cells isolated from aviremic patients on
cART. Cultures of Isolated PBMC depleted of CD8+ T cells and cultures of resting CD4+ T cells expressed
HIV-1 RNA levels to a degree comparable to that obtained after anti-CD3+anti-CD28 antibodies stimulation in presence of JQ1/Ing-B+bryostatin-1 [61] . The mechanism of action underlying the synergism was also partially uncovered: it seems, in fact, that on the one hand JQ1 increased bryostatin-1-induced NF-κB DNAbinding activity and on the other hand that JQ1 and bryostatin-1 caused a higher activation of P-TEFb than the compounds alone [61] . Finally, the activity of PKC agonists plus JQ1 on cell surface activation markers was investigated. They noted that first, JQ1 did not cause the activation of resting CD4+ T cells and CD4+ cells -analyzed from the CD8-depleted pool -and second, that the combination of PKC agonists and JQ1 led to the activation of cell markers such as CD69 and HLA-DR and to a downregulation of CD38 and CD25 compared with the PKC agonists effect alone. Consequently, it is reasonable to say that the combination causes a minor T cell activation which is fundamental towards a clinical prospective, since compounds which trigger a non-specific or robust immune activation are inappropriate for in vivo applications.
Moreover, the combination PKC agonist plus JQ1 led to the downregulation of CD4 receptor, which could be beneficial for the blockade of de novo HIV infections [61] .
A c c e p t e d M a n u s c r i p t HIV-RNA levels and is capable of stimulating the production of INF-α, which plays a key role in HIV induction [65] . Besides, it was discovered that GS-9620 can upregulate the expression of CD69 and consequently activate CD4 and CD8 both in the presence and absence of HIV antigens, even though in the first case the level is much higher [65] . Furthermore, it was noticed that the molecule was able to enhance the CD8 cytolytic effect and that this same effect is strictly connected with the activation of IFN-α (62). Finally, Tsai et al. proved that immune effector cells, like monocyte and dendritic cells, due to the upregulation of CD80
as well as CD69 consequent to the exposure to GS-9620, more effectively recognize and kill HIV-infected target cells in the presence of effector-competent bNAbs [65] . Also, maraviroc have been investigated among LRAs, alone or combined with PKC-agonists, in fact this CCR5 antagonist can activate NF-κB and, subsequently, induce latent HIV-1-transcription in resting CD4 + T-cells from HIV-1-infected individuals on suppressive antiretroviral therapy [66, 67] .
A c c e p t e d M a n u s c r i p t 
Immune therapy
A detailed understanding of how the host immune system shapes the size and distribution of the viral reservoir should lead to the development of a new generation of immune-based therapeutics, which might eventually contribute to a curative intervention [78] . CTLA-4+/ programmed death-1(PD1)-CD4+ T cells with controls [84] . It was proved that the administration of PD-1 antibody to SIV-infected macaques resulted in a rapid expansion of CD8+ T cells with a reduction in the interferon signaling pathways and reduction in intestinal microbial translocation [85, 86] . Moreover, a single study in a patient with metastatic melanoma and HIV treated with anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) antibodies showed an increase in cell-associated HIV-1 RNA [87, 88] . So far, the only trial assessing an immune checkpoint blocker in individuals with HIV infection without malignancy was a phase II dose-escalation study with an anti-PDL1
antibody (BMS-936559), which was prematurely interrupted for concomitant retinal toxicity in a simultaneous study in macaques. Moreover, one patient, among the six tested, developed hypophysitis A c c e p t e d M a n u s c r i p t 17 after several months from the discontinuation of the compound, thus raising concern about the safety of this class of compounds [89] . Furthermore, a recent study released on June 2018 by Porichis et al describes the relationship between restored CD4+ T cells and NK cells [90] . It has been shown the importance of other interleukins, i.e. IL-15, in enhancing the survival and also the effector function of HIV specific CD8+ specific lymphocytes which are fundamental for the control of HIV replication [91] . Recent data have shown how the use of IL-15 superagonist ALT-803 is able to invert the trafficking of SIV specific CD8+ cells from peripheral blood to lymph nodes, and in particular inside B cells follicles [92] . Moreover, in rhesus macaques IL-15 superagonist ALT-803 has the ability to increase both NK cells and CD8 + cells with an impact in the reduction of SIV viremia, albeit transiently [93] .
Non pharmacological strategies

Broadly neutralizing antibodies
Along with the discovery of numerous HIV-1-specific broadly neutralizing antibodies (bNAbs) [94] [95] [96] , it has become evident that viral co-evolution is likely required to induce potent bNAbs during the natural course of infection by mature B lymphocytes [97, 98] . One of the bNAbs' possible mechanisms of action against HIV infected cells may be the increase of the host immunity or FcγR-dependent mechanism by forming an immune complex for eliciting CD8+ T cell responses [99, 100] . Previous studies have shown that bNAbs A c c e p t e d M a n u s c r i p t administered at the time of ART discontinuation can provide direct antiviral effects, but whether bNAbs can effectively target the viral reservoir during ART suppression remains to be determined. Recent work has shown that bNAbs can clear cell-free virus and infected cells that express HIV [101] . Proviral DNA was reduced in macaques treated with these antibodies [102, 103] . However, the extent of the antibodies ability to clear latently infected cells is not well understood. The first bNAbs studied in the VRC01 phase I study showed that a single infusion was associated with various degrees of viral suppression in viremic patients ranging from a sustained suppression of HIV replication to no inhibition of viral replication [104] .
The emergence of resistant virus strains has arisen as the major problem with this therapeutic approach leading to the recrudescence of viral replication in plasma after a median time of about five weeks after cART interruption, albeit therapeutic levels of VRC01 were detected [105] . Similar findings have been observed in a analogous investigation by using 3BNC117 bNAbs [106] . The next step in the development of such types of bNAbs has been the increase of the potency of the autoantibodies combined with a broader coverage of the envelope escaping variants. Engineering strategy has led to the extension of the half-life of this bNAbs by modifying the Fc region causing a block of the endosomal degradation. Moreover, this new technology has permitted the co-formulation of different bNabs in a single compound accounting for a greater breadth of coverage when compared to first generation bNAbs [107, 108] . in vitro and ex-vivo data have shown how bispecific antibodies directed against GP-120 HIV surface protein, using either the scFv B12 or VRC01, are able to inhibits HIV replication not only in PBMCs but also in macrophages co-cultured with autologous CD8+ T-cells. The combination of these antibody constructs with latency reversible agents could potentially be an option to taking into account as future approach for HIV-cure since has shown an efficient killing of GP-120 expressing cells and the inhibition of HIV replication both in PBMCs as well as in macrophages [109] . An in vivo study, in humanized mice, has shown that an injection of a bispecific bNAns, Several human studies are planned in order to evaluate the effects of passively infused antibodies on the HIV reservoir. Immune checkpoint blockers such as anti-programmed cell death-1 antibody could improve function and persistence of effector T cells [78] . Targeted cytotoxic therapy using immunotoxin is another potential path [111] . One of the possible bNAbs routs of administration assessed was the delivery by an adeno associated virus in rhesus monkeys with the achievement of a sustained viral remission by using two different bNAbs [112] . One of the last drugs developed for HIV treatment is an anti-CD4 (IgG4 humanized) monoclonal antibody, ibalizumab [117] . Ibalizumab was developed initially for HIV prevention strategies and actually is licensed for the treatment of drug resistance viruses as a component of salvage strategies [118] . Although A c c e p t e d M a n u s c r i p t 20 ibalizumab showed in a phase 3 study to be effective against multi-drug resistance viruses, the development of escape mutants has been observed [119] .
Another humanized monoclonal antibody is PRO 140, which binds to CCR5 inhibiting R5 tropic viruses without any role in blocking CXCR4-using viruses [120] . This compound was tested in a phase II study administered intravenously in which a single intravenous infusion has been demonstrated to have potent, long-lasting antiretroviral activity with a favourable safety profile [121] . Nowadays, there are ongoing phase IIb and III trials in patients with virologic failure and as monotherapy maintenance strategy in patients with viral suppression [122] .
Gene and cell therapy
As it has previously mentioned, the anecdotal case of the "Berlin patient" highlights the possibility of HIV eradication by allopoietic bone marrow cells transplantation with implanted cells intrinsically resistant to HIV infection [11] . Nevertheless, this case was not further reproduced; a recent work by Colonna et al. in
cART-suppressed non-human primates infected by SIV showed how allopoietic hematopoietic cell transplantation is insufficient for HIV eradication despite high-level donor chimerism and graft versus host disease due to the persistence of HIV in multiple sites including the brain [123] . Nowadays, several strategies based on gene and cell therapy have been tested in order to evaluate HIV cure approaches from in vitro studies to clinical trial [124] . These include engineering HIV-specific immunity in T-cells, gene editing approaches to render all blood cells in the body HIV-resistant starting from the proof of concept of the "Berlin patient", and a combination of both these strategies. As for pharmacological intervention, it is unlikely that a single intervention could lead to complete HIV eradication. Conversely, a combination of multiple intervention based on cell and gene therapy are more likely to give some results.
Conclusion
In this review, we assessed several pharmacological strategies, which have been tested as HIV curative In regards to "shock and kill", which is the most widely investigated among curative intervention strategies, the great challenge is the possibility to apply in vitro and ex vivo discovery firstly to animal model and secondly to clinical practice. This gap is unfortunately not negligible and the great majority of research in the field had the limit of the difficult applicability in vivo. In fact, when we face up with new interventions we have to take into account important ethical, social and behavioural research questions in parallel [125, 126] . The great majority of these strategies poses significant health risks with realistically modest benefit to trial participants. Moreover, the proof of concept of HIV cure and remission is the structured treatment interruption. If on the one hand we could limit the potential problems related to viral rebound for the subject with a close monitor and a rapid resumption of cART, on the other hand we pose the subject in a condition of medicalization that would not be necessary if the patient was still on cART. Furthermore, the effect of a potential resettlement of the viral reservoir during cART interruption is unclear [127] .
A c c e p t e d M a n u s c r i p t Since every single strategy alone have failed to reach the ambitious goal of curing HIV, the next step will be the development of multiple steps and target interventions, thus considering the combination of pharmacological and immune agents, i.e. LRA, inflammatory pathway blockage, therapeutic vaccines and other interventions. The objective is at least to induce a cART free remission and whether possible a complete viral eradication.
After the description of the VISCONTI cohort [25] and the explanation of the "shock and kill" [29] line of research, the field of the HIV cure has been dramatically developed. Together with excellent data and sporadic pitfalls, alternate waves of hope and discomfort are still present in the most prominent research initiatives.
The "Berlin patient" remains a great success, yet anecdotal. In parallel, the "Mississippi" and "Milan" babies and the "Boston" patients [18, 27, 128] revealed that the reality is harsher that scientific promises, although well built. As clinicians and researchers who care for HIV-positive patients, we do not know if these strategies will ever be feasible, but we surely realize that it is worth trying to find a solution. In the next 5 years, a series of issues need to be elucidated, as a substantial step before adding them into the clinical practice, such as (i) identifying biomarkers that do rationally have an impact on the inflammation profile and (ii) ways of measuring the viral reservoir. This couple of activities aim at assessing both sides of the same medal, i.e. the reaction by the immune system and the ways in which HIV replicates or hides. The challenge will be to measure them in the most effective and accurate way.
A c c e p t e d M a n u s c r i p t
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Other than these obstacles, some approaches look in a better shape than others and will be more extensively developed in the next 5 years. These tools will include (i) several check-point inhibitors developed in cancer research, the most promising being those which block the axis PD-1/PDL-1 and CTLA-4 and (ii) multiple broadly neutralizing antibodies, some of which already concluded clinical trials.
It is not going to be a déjà vu and the best way to use these new resources will be as multi-target combination therapies, which, as expected, will need to take into consideration not only the power of the combination but the complex burden of side effects.
Article highlights
• In the early phases of HIV infection the establishment of a reservoir composed by quiescent and long lasting cells represents the major obstacle to HIV eradication.
• Intervention strategies in acute HIV infection could lead to a significant reduction in the reservoir's size but inexorably HIV-RNA rebounds in plasma after cART interruption even if the reservoir result unquantifiable.
• Shock and kill strategies have the aim of revert the latency of quiescent cells composing the HIV reservoir and subsequently kill the same cell. Several models have demonstrated how this kind of intervention can be effective in vitro and in animal model, but at the moment no strategy has been demonstrated to be effective in reducing the reservoir size in clinical studies.
• Immunological strategies accounting for the use of check-point inhibitors developed in cancer research seems to be promising. To date, the major concern regards the safety profile for this class of compounds.
• Broadly neutralizing antibodies represent not only an option among strategies for long term control of HIV viremia and HIV prevention but they could be also part of combined strategies for targeting HIV reservoir as a part of kill interventions.
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• Since every single strategy has failed in HIV eradication, the future interventions will have to focus on multitarget combination therapies. M a n u s c r i p t
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